Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

Arzoxifene ([6-hydroxy-3-[4-[2-(1-piperidinyl)-ethoxy]phenoxy]-2-(4-methoxyphenyl)]benzo[b]thiophene) is a selective estrogen receptor modulator (SERM) that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol. Arzoxifene is a highly effective agent for prevention of mammary cancer induced in the rat by the carcinogen nitrosomethylurea and is significantly more potent than raloxifene in this regard. Arzoxifene is devoid of the uterotrophic effects of tamoxifen, suggesting that, in contrast to tamoxifen, it is unlikely that the clinical use of arzoxifene will increase the risk of developing endometrial carcinoma.

[1]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[2]  V. Jordan,et al.  Selective oestrogen receptor modulation: molecular pharmacology for the millennium. , 1999, European journal of cancer.

[3]  M. Sporn,et al.  Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. , 1994, Cancer research.

[4]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[5]  V. Jordan,et al.  Selective estrogen receptor modulation: a personal perspective. , 2001, Cancer research.

[6]  B. Weber,et al.  Prophylactic mastectomy--the price of fear. , 1999, The New England journal of medicine.

[7]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[8]  M. Sporn,et al.  A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis , 1999 .

[9]  Shannon K. McDonnell,et al.  EFFICACY OF BILATERAL PROPHYLACTIC MASTECTOMY IN WOMEN WITH A FAMILY HISTORY OF BREAST CANCER , 1999 .

[10]  Harry Hollema,et al.  Risk and prognosis of endometrial cancer after tamoxifen for breast cancer , 2000, The Lancet.

[11]  G. Weryha,et al.  Selective estrogen receptor modulators. , 1999, Current opinion in rheumatology.

[12]  D. McDonnell,et al.  The Molecular Pharmacology of SERMs , 1999, Trends in Endocrinology & Metabolism.

[13]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[14]  D. Bentrem,et al.  Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[16]  B. Gusterson,et al.  Comparative study of human and rat mammary tumorigenesis. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[17]  J. Gustafsson,et al.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.

[18]  C. Turner,et al.  LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. , 1998, The Journal of pharmacology and experimental therapeutics.

[19]  R. Dickson,et al.  ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. , 1989, Cancer research.

[20]  T. Rebbeck,et al.  Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Lippman,et al.  Interactions of antiestrogens with human breast cancer in long-term tissue culture. , 1976, Cancer treatment reports.

[22]  H. Storm,et al.  Endometrial carcinoma and tamoxifen: clearing up a controversy. , 1996, Clinical Cancer Research.

[23]  D. Bentrem,et al.  Tamoxifen, raloxifene and the prevention of breast cancer. , 2002, Minerva endocrinologica.

[24]  M. Lippman,et al.  Antiestrogenic effects of LY 117018 in MCF-7 cells. , 1983, Endocrinology.

[25]  B. Katzenellenbogen,et al.  Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. , 1987, Cancer research.

[26]  M. Sporn,et al.  Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. , 1996, Journal of the National Cancer Institute.